Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 424 in Relapsed/Refractory Multiple Myeloma
NCT03445663Phase 1Terminated
- Sponsor
- Xencor
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of XmAb18968 in multiple myeloma (MM), sponsored by Xencor. Primary endpoints: Subject incidence of treatment emergent and treatment related adverse events at 12 Months and Subject incidence of dose limiting toxicities at 28 Days. Started Jul 2018; status: terminated.
02
Drugs
XmAb18968
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03445663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03445663.